Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ULS

UL Solutions Inc

May 06 • 04:00PM ET

36.07

Dollar change +0.67
Percentage change 1.89	%

Industrials • Specialty Business Services • USA • NYSE

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: WCEO

Index	-	P/E	27.75	EPS (ttm)	1.30	Insider Own	80.97%	Shs Outstand	200.00M	Perf Week	3.29%
Market Cap	7.21B	Forward P/E	-	EPS next Y	-	Insider Trans	-19.12%	Shs Float	38.05M	Perf Month	-
Income	260.00M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Sales	2.68B	P/S	2.69	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Book/sh	3.27	P/B	11.03	EPS next Y	-	ROA	9.53%	Short Interest	-	Perf Year	-
Cash/sh	1.57	P/C	22.90	EPS next 5Y	-	ROE	30.44%	52W Range	33.15 - 35.93	Perf YTD	3.23%
Dividend Est.	-	P/FCF	28.63	EPS past 5Y	-	ROI	15.49%	52W High	0.39%	Beta	-
Dividend TTM	-	Quick Ratio	1.34	Sales past 5Y	5.26%	Gross Margin	47.80%	52W Low	8.81%	ATR (14)	0.96
Dividend Ex-Date	-	Current Ratio	1.34	EPS Y/Y TTM	-11.26%	Oper. Margin	15.16%	RSI (14)	-	Volatility	2.50% -
Employees	15233	Debt/Eq	1.63	Sales Y/Y TTM	6.27%	Profit Margin	9.71%	Recom	-	Target Price	-
Option/Short	Yes / Yes	LT Debt/Eq	1.57	EPS Q/Q	-25.64%	Payout	-	Rel Volume	0.16	Prev Close	35.40
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	8.74%	Earnings	-	Avg Volume	1.88M	Price	36.07
SMA20	4.79%	SMA50	4.79%	SMA200	4.79%	Trades		Volume	295,998	Change	1.89%

Apr-18-24 07:01PM	Director Marla Gottschalk Acquires 71,428 Shares of UL Solutions Inc (ULS) (GuruFocus.com)
07:01PM	Director James Dollive Acquires 71,428 Shares of UL Solutions Inc (ULS) (GuruFocus.com)
07:01PM	Director Kevin Kennedy Acquires 35,714 Shares of UL Solutions Inc (ULS) (GuruFocus.com)
07:00PM	UL Solutions Inc CEO Jennifer Scanlon Acquires 89,285 Shares (GuruFocus.com)
Apr-12-24 04:09PM	UL Solutions Finally Debuts, Stock Jumps (The Wall Street Journal)
02:55PM	Loading…
02:55PM	Thrilled To Up-Size IPO: UL Solutions CEO (Bloomberg)
01:12PM	UPDATE 3-UL Solutions valued at $6.8 bln in strong debut on NYSE (Reuters)
01:04PM	Safety testing firm UL Solutions' shares rise 21% in market debut (Reuters)
Apr-11-24 09:57PM	Safety Firm UL Solutions Upsized IPO Raises $946 Million (Bloomberg)
09:37PM	UL Solutions Announces Pricing of Upsized Initial Public Offering (Business Wire)

UL Solutions, Inc. provides testing, inspection and certification services. It offers facility, personnel, system, energy efficiency, indoor air quality and wireless services. The company serves through two complementary businesses, TIC and E&A. TIC business is made up of two reportable segments, industrial and consumer, which provide comprehensive testing, inspection and certification services to customers across a broad array of end markets. E&A business provides subscription and license-based software and advisory services to support customers' risk management, sustainability and compliance processes. The company was founded by William Henry Merrill Jr. in 1893 and is headquartered in Northbrook, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Coyne Frank J	Director	Apr 16 '24	Buy	28.00	107,142	2,999,976	107,142	Apr 18 04:32 PM
Scanlon Jennifer F.	President and CEO	Apr 16 '24	Buy	28.00	89,285	2,499,980	89,285	Apr 18 04:30 PM
DOLLIVE JAMES P	Director	Apr 16 '24	Buy	28.00	71,428	1,999,984	71,428	Apr 18 04:33 PM
Robinson Ryan D	Executive VP & CFO	Apr 16 '24	Buy	28.00	71,428	1,999,984	71,428	Apr 18 04:32 PM
GOTTSCHALK MARLA C	Director	Apr 16 '24	Buy	28.00	71,428	1,999,984	71,428	Apr 18 04:33 PM
KENNEDY KEVIN	Director	Apr 16 '24	Buy	28.00	35,714	999,992	35,714	Apr 18 04:33 PM
Zhou Weifang	See Remarks	Apr 16 '24	Buy	28.00	26,786	750,008	26,786	Apr 18 04:32 PM
Genovesi John A	See Remarks	Apr 16 '24	Buy	28.00	18,000	504,000	18,000	Apr 18 04:30 PM
McLaughlin Jacqueline K	EVP & CLO	Apr 16 '24	Buy	28.00	17,857	499,996	17,857	Apr 18 04:31 PM
Schjotz Gitte	See Remarks	Apr 16 '24	Buy	28.00	17,857	499,996	17,857	Apr 18 04:30 PM
Hecker Friedrich	Director	Apr 16 '24	Buy	28.00	10,714	299,992	10,714	Apr 18 04:34 PM
Uggetti Alberto	EVP & CCO	Apr 16 '24	Buy	28.00	9,285	259,980	9,285	Apr 18 04:31 PM
THAMAN MICHAEL H	Director	Apr 16 '24	Buy	28.00	8,928	249,984	8,928	Apr 18 04:33 PM
WILLIAMS GEORGE A	Director	Apr 16 '24	Buy	28.00	8,928	249,984	8,928	Apr 18 04:34 PM
Shannon James M	Director	Apr 16 '24	Buy	28.00	7,142	199,976	7,142	Apr 18 04:34 PM
Hancock Lynn H	See Remarks	Apr 16 '24	Buy	28.00	5,000	140,000	5,000	Apr 18 04:31 PM
PEPPING KAREN K	Senior VP & CAO	Apr 16 '24	Buy	28.00	3,571	99,988	3,571	Apr 18 04:35 PM
Torstad Elizabeth	Director	Apr 16 '24	Buy	28.00	3,571	99,988	3,571	Apr 18 04:34 PM
SUSMAN SALLY	Director	Apr 16 '24	Buy	28.00	3,571	99,988	3,571	Apr 18 04:32 PM
Chapin Linda S	EVP & CHRO	Apr 16 '24	Buy	28.00	1,785	49,980	1,785	Apr 18 04:34 PM
Lambert Lisa Marie	Director	Apr 16 '24	Buy	28.00	892	24,976	892	Apr 18 04:32 PM
Hooper Charles W	Director	Apr 16 '24	Buy	28.00	357	9,996	357	Apr 18 04:31 PM
ULSE Inc.	10% Owner	Apr 16 '24	Sale	28.00	38,870,000	1,088,360,000	0	Apr 18 06:05 PM

Open in Screener

NEO

Neogenomics Inc.

May 06 • 04:00PM ET

15.51

Dollar change +0.21
Percentage change 1.37	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IJR VTI VB IWM VXF VBK IJT IWN SCHA VIOO

Index	RUT	P/E	-	EPS (ttm)	-0.67	Insider Own	1.15%	Shs Outstand	127.37M	Perf Week	1.91%
Market Cap	1.98B	Forward P/E	94.56	EPS next Y	0.16	Insider Trans	-0.77%	Shs Float	126.25M	Perf Month	3.95%
Income	-84.23M	PEG	-	EPS next Q	-0.00	Inst Own	99.37%	Short Float	6.05%	Perf Quarter	9.46%
Sales	610.66M	P/S	3.24	EPS this Y	117.78%	Inst Trans	-4.36%	Short Ratio	8.06	Perf Half Y	7.56%
Book/sh	7.25	P/B	2.14	EPS next Y	668.69%	ROA	-5.03%	Short Interest	7.64M	Perf Year	7.34%
Cash/sh	3.01	P/C	5.15	EPS next 5Y	-	ROE	-8.88%	52W Range	11.03 - 21.22	Perf YTD	-4.14%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-5.52%	52W High	-26.91%	Beta	1.18
Dividend TTM	-	Quick Ratio	7.22	Sales past 5Y	17.35%	Gross Margin	38.51%	52W Low	40.62%	ATR (14)	0.75
Dividend Ex-Date	-	Current Ratio	7.48	EPS Y/Y TTM	33.62%	Oper. Margin	-15.46%	RSI (14)	59.11	Volatility	6.00% 4.86%
Employees	2100	Debt/Eq	0.66	Sales Y/Y TTM	15.27%	Profit Margin	-13.79%	Recom	1.46	Target Price	20.45
Option/Short	Yes / Yes	LT Debt/Eq	0.65	EPS Q/Q	12.87%	Payout	-	Rel Volume	0.59	Prev Close	15.30
Sales Surprise	4.26%	EPS Surprise	49.62%	Sales Q/Q	13.86%	Earnings	Apr 30 BMO	Avg Volume	948.07K	Price	15.51
SMA20	9.06%	SMA50	3.78%	SMA200	1.08%	Trades		Volume	562,510	Change	1.37%

Date	Action	Analyst	Rating Change	Price Target Change
May-01-24	Resumed	Craig Hallum	Buy	$26
Dec-29-23	Reiterated	BTIG Research	Buy	$25 → $21
Aug-21-23	Upgrade	Stephens	Equal-Weight → Overweight	$18
May-16-23	Downgrade	Raymond James	Outperform → Mkt Perform
May-09-23	Upgrade	BTIG Research	Neutral → Buy	$25
Feb-24-23	Upgrade	The Benchmark Company	Hold → Buy	$20
Feb-01-23	Upgrade	Needham	Hold → Buy	$15
Aug-26-22	Downgrade	The Benchmark Company	Buy → Hold
Aug-22-22	Downgrade	Needham	Buy → Hold
Jun-03-22	Initiated	Piper Sandler	Overweight	$13
Mar-29-22	Downgrade	Stephens	Overweight → Equal-Weight	$34 → $16
Mar-29-22	Downgrade	BofA Securities	Buy → Neutral	$25 → $18
Jan-18-22	Resumed	Stephens	Overweight	$40
Dec-16-21	Initiated	Cowen	Outperform	$42
Nov-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-14-21	Upgrade	Raymond James	Mkt Perform → Outperform	$53
Jun-03-21	Initiated	Goldman	Buy	$55
Feb-25-21	Resumed	Needham	Buy	$65
Feb-25-21	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-28-21	Initiated	Truist	Buy	$65

Show Previous Ratings

May-02-24 02:14PM	NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.44%
May-01-24 03:04AM	NeoGenomics Inc (NEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and ... (GuruFocus.com)
Apr-30-24 11:53AM	NEO Stock Earnings: NeoGenomics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -8.54%
11:25AM	Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating (MT Newswires)
10:30AM	Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q1 Earnings (Zacks)
08:52AM	Loading…
08:52AM	NeoGenomics Q1 2024 Earnings: Revenue Surpasses Estimates, Net Loss Narrows (GuruFocus.com)
08:40AM	NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:37AM	NeoGenomics: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	NeoGenomics Reports First Quarter 2024 Results (Business Wire)
Apr-23-24 10:00AM	NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks) +5.51%
Apr-18-24 07:05AM	NeoGenomics Announces Senior Leadership Promotions (Business Wire)
Apr-09-24 07:00AM	NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024 (Business Wire)
Mar-27-24 08:30AM	NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting (Business Wire)
Mar-20-24 12:00PM	All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy (Zacks) +5.57%
09:55AM	Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect? (Zacks)
07:00AM	Loading…
07:00AM	NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report (Business Wire)
Mar-01-24 07:05AM	NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference (Business Wire)
Feb-29-24 08:12AM	Natera, Inc. (NASDAQ:NTRA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 09:55AM	Wall Street Analysts Predict a 29.57% Upside in NeoGenomics (NEO): Here's What You Should Know (Zacks)
Feb-21-24 09:57AM	NeoGenomics, Inc. (NASDAQ:NEO) Q4 2023 Earnings Call Transcript (Insider Monkey) +12.11%
06:38AM	Q4 2023 Neogenomics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-20-24 07:00PM	NeoGenomics (NEO) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:35PM	NeoGenomics (NEO) Q4 Earnings and Revenues Beat Estimates (Zacks)
04:39PM	NeoGenomics Inc (NEO) Reports Growth in Revenue and Reduction in Net Loss for Q4 and Full Year 2023 (GuruFocus.com)
04:37PM	NeoGenomics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	NeoGenomics Reports Fourth Quarter and Full Year 2023 Results (Business Wire)
Feb-01-24 07:05AM	NeoGenomics Signs Working with Cancer Pledge in Support of Employees (Business Wire)
Jan-30-24 09:15AM	Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030 (GlobeNewswire) -5.61%
07:05AM	NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024 (Business Wire)
Jan-12-24 05:20AM	Bull of the Day: NeoGenomics (NEO) (Zacks)
07:05AM	Loading…
Jan-02-24 07:05AM	NeoGenomics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-28-23 04:30PM	S&P 500 Misses Out On Record As Stock Market Fades Late; Small Caps On Pace For Record December (Investor's Business Daily) -18.10%
03:08PM	S&P 500 Near Record High As These 3 Dow Stocks Test Buy Points (Investor's Business Daily)
12:07PM	Altice USA, PENN Entertainment rise; Hess, NeoGenomics fall, Thursday, 12/28/2023 (Associated Press Finance)
08:10AM	NeoGenomics to Appeal Ruling (ACCESSWIRE)
Dec-05-23 08:00AM	NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response (ACCESSWIRE)
Nov-14-23 07:00AM	NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference (ACCESSWIRE) +8.71%
Nov-13-23 09:55AM	Wall Street Analysts See a 28.17% Upside in NeoGenomics (NEO): Can the Stock Really Move This High? (Zacks)
Nov-07-23 09:01AM	NeoGenomics, Inc. (NASDAQ:NEO) Q3 2023 Earnings Call Transcript (Insider Monkey) +14.20%
Nov-06-23 09:00PM	Compared to Estimates, NeoGenomics (NEO) Q3 Earnings: A Look at Key Metrics (Zacks)
06:10PM	NeoGenomics: Q3 Earnings Snapshot (Associated Press Finance)
04:33PM	NeoGenomics Inc (NEO) Reports 18% Revenue Increase in Q3 2023 (GuruFocus.com)
04:05PM	NeoGenomics Reports Third Quarter 2023 Results (ACCESSWIRE)
Nov-01-23 10:01AM	Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
10:00AM	NeoGenomics (NEO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-27-23 09:55AM	Wall Street Analysts Think NeoGenomics (NEO) Could Surge 35.08%: Read This Before Placing a Bet (Zacks) -6.20%
Oct-24-23 07:00AM	NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios (ACCESSWIRE) +7.59%
05:20AM	Bull of the Day: NeoGenomics (NEO) (Zacks)
02:18AM	NeoGenomics and SolarEdge Technologies have been highlighted as Zacks Bull and Bear of the Day (Zacks)
Oct-18-23 08:26AM	NeoGenomics (NEO) Soars 8.9%: Is Further Upside Left in the Stock? (Zacks)
Oct-17-23 09:20AM	NeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023 (ACCESSWIRE) +8.85%
09:15AM	Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030 (PR Newswire)
Oct-13-23 12:00PM	NeoGenomics (NEO) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Aug-08-23 11:30AM	NeoGenomics (NEO) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
09:22AM	NeoGenomics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	NeoGenomics Reports Second Quarter 2023 Results (ACCESSWIRE)
Jul-27-23 07:00AM	NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer (ACCESSWIRE) -5.67%
Jul-18-23 07:10AM	NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023 (ACCESSWIRE)
Jun-29-23 07:00AM	NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors (ACCESSWIRE)
Jun-21-23 08:00PM	NEO: Rating increased to a HOLD (Argus Research)
Jun-15-23 04:45PM	NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage (ACCESSWIRE)
Jun-08-23 01:36PM	Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking (Simply Wall St.)
Jun-06-23 08:02AM	The Proxies: A celebration of substantial corporate perks (Financial Times)
Jun-05-23 07:00AM	NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer (ACCESSWIRE) -7.73%
Jun-01-23 07:00AM	NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference (ACCESSWIRE)
May-30-23 07:00AM	NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO (ACCESSWIRE)
May-17-23 08:16AM	Zacks.com featured highlights include First Watch Restaurant, NeoGenomics and Universal Stainless & Alloy Products (Zacks)
May-16-23 06:59AM	3 Best Breakout Stocks to Invest in for Superlative Returns (Zacks) -6.48%
May-10-23 01:26AM	4 big analyst picks: Alcon upgraded to Outperform after Q1 beat \| Pro Recap (Investing.com) +7.67%
May-09-23 01:39PM	NeoGenomics Reports Q1 Topline Growth, Lifts Annual Guidance, Shares Soar (Benzinga) +18.51%
May-08-23 06:15PM	NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:02PM	NeoGenomics: Q1 Earnings Snapshot (AP Finance)
04:05PM	NeoGenomics Reports First Quarter 2023 Results (ACCESSWIRE)
May-03-23 07:00AM	NeoGenomics to Participate at the BofA Securities 2023 Healthcare Conference (ACCESSWIRE)
May-01-23 06:29AM	Zacks.com featured highlights Portillo's, NeoGenomics and Wingstop (Zacks)
Apr-26-23 08:00PM	NEO: Raising target price to $15.00 (Argus Research)
Apr-17-23 07:00AM	NeoGenomics to Announce First Quarter 2023 Financial Results (ACCESSWIRE) +5.74%
Apr-14-23 06:51AM	Zacks.com featured highlights include Lamb Weston, NeoGenomics, Surrozen, KE Holdings and Insperity (Zacks)
Apr-11-23 07:00AM	NeoGenomics to Participate at the 22nd Annual Needham Virtual Healthcare Conference (ACCESSWIRE)
Apr-06-23 07:00AM	NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023 (ACCESSWIRE)
Mar-27-23 07:00AM	NeoGenomics to Host Investor Day on April 4, 2023 (ACCESSWIRE)
Mar-22-23 08:00AM	Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care (Business Wire)
Mar-21-23 08:06AM	NeoGenomics' (NASDAQ:NEO) growing losses don't faze investors as the stock grows 4.7% this past week (Simply Wall St.)
Mar-19-23 06:24AM	3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing (Motley Fool)
Mar-16-23 07:00AM	NeoGenomics Announces Commercial Availability of the RaDaR(R) Molecular Residual Disease Test (ACCESSWIRE)
Mar-13-23 07:00AM	NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM) - Solid Tumor CGP and Neo Comprehensive(TM) - Myeloid Disorders CGP (ACCESSWIRE) +5.19%
Feb-28-23 07:00AM	NeoGenomics to Present at the 44th Annual Raymond James Institutional Investors Conference (ACCESSWIRE)
Feb-23-23 03:34PM	Why Shares of NeoGenomics Jumped Today (Motley Fool) +24.57%
03:32PM	Why NeoGenomics Shares Are Trading Higher Today (Benzinga)
10:05AM	NeoGenomics (NEO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	NeoGenomics Reports Fourth Quarter and Full Year 2022 Results (ACCESSWIRE)
Feb-06-23 07:00AM	RaDaR(R) Assay Demonstrates Clinical Potential for Helping Oncologists Determine Whether or Not Muscle-Invasive Bladder Cancer Patients Undergo Radical Surgery (ACCESSWIRE) -6.45%
07:00AM	NeoGenomics Schedules its Fourth Quarter and Full Year 2022 Earnings Release for February 23, 2023 (ACCESSWIRE)
Dec-12-22 09:55AM	Wall Street Analysts Predict a 41% Upside in NeoGenomics (NEO): Here's What You Should Know (Zacks)
Dec-05-22 07:50PM	NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (ACCESSWIRE)
07:35PM	NeoGenomics Announces Chief Financial Officer Transition (ACCESSWIRE)
Nov-21-22 07:00AM	RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease (ACCESSWIRE)
Nov-18-22 09:20AM	NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM) (ACCESSWIRE)
Nov-11-22 05:36PM	Why Shares of NeoGenomics Jumped 53.9% This Week (Motley Fool) +11.61%

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TETRAULT LYNN A.	Director	Mar 04 '24	Sale	15.97	6,112	97,579	50,062	Mar 06 04:26 PM
Olivo Alicia C	General Counsel	Feb 15 '24	Sale	14.96	2,587	38,713	34,866	Feb 20 04:32 PM
Olivo Alicia C	General Counsel	Nov 17 '23	Sale	18.39	2,669	49,083	37,140	Nov 20 04:33 PM
TETRAULT LYNN A.	Director	May 22 '23	Option Exercise	11.60	1,507	17,481	56,174	May 24 05:29 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ULS

UL Solutions Inc

NEO

Neogenomics Inc.

Upgrade your FINVIZ experience